Abstract: The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract: A dashboard interface may be displayed on a lab instrument to provide aggregate status information from a plurality of other interfaces organized into a single interface. The aggregate status information may be viewed by a nearby user of the lab instrument, and selecting portions of the information via a touchscreen display will navigate directly to a subsequent interface that may be used to view additional information or make configuration changes relating to the selected information. The dashboard may be used as a screensaver on a lab instrument when the instrument is not in use, or may be navigated to by an active user of a lab instrument, or both.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: Fluid additives suitable for use in a wellbore (e.g., a liquid comprising an aqueous miscible fluid, a liquid surfactant, or both) may be converted into a liquid-infiltrated porous silica that is a flowable bulk solid. The flowable bulk solid may then be handled and stored as a traditional solid wellbore additive. For example, the flowable bulk solid may be added to an aqueous fluid to produce a wellbore fluid that is then introduced into a wellbore penetrating a subterranean formation.

Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.

Abstract: A horn having folded axial corrugations is provided. The horn includes folded axial corrugations for a compact, low-profile, high-efficiency, and high power handling performance. The folded axial corrugations may include a plurality of grooves that are symmetric about a central axis, each groove including an axial portion that extends in a direction parallel to the central axis and a radial portion that extends from an end of the axial portion in a direction perpendicular to the central axis.

Abstract: The invention relates to recombinant microorganisms and methods for producing gibberellin compounds and gibberellin precursors.

Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

Abstract: A monitoring system configured to receive an on-line sample associated with a process includes a sample chamber positioned to receive the on-line sample and a detector positioned to selectively receive and detect multiple wavelengths of light transmitted through the sample during an absorbance measurement, and emitted by the sample during a fluorescence measurement in response to illumination by each of the at least one excitation wavelength. An optical fiber couples light transmitted through the sample and directs the transmitted light to the multi-channel detector during the absorbance measurement. Optics direct light emitted by the sample during the fluorescence measurement to the detector without passing through any optical fiber. A computer in communication with the detector is configured to correct the fluorescence measurement using the absorbance measurement and determine a sample parameter based on the fluorescence and absorbance measurements of the on-line sample.

Abstract: Variables utilized in device firmware that provides various boot and runtime services are repaved in a fault-tolerant manner within a secure store in a durable, non-volatile device memory during an FOTA update process. A spare region in the secure store is utilized to temporarily hold a back-up of a primary region in which the firmware variables are written. Using a transaction-based fault-tolerant write (FTW) process, the variables in the primary region can be repaved with variables contained in a firmware update payload that is delivered from a remote service. In the event of a fault in the variable region repaving process, either the primary or spare region will remain valid so that firmware in a known good state can be utilized to enable the device to boot successfully and the variable region repaving in the FOTA update process may be restarted.

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Abstract: A system or method for analyzing a sample include an input light source, an excitation light source positioned to receive light from the input light source and to sequentially illuminate the sample with each of a plurality of wavelengths, a fluorescence detector positioned to receive and substantially simultaneously detect multiple wavelengths of light emitted by the sample for each of the plurality of excitation wavelengths, an absorption detector positioned to receive and detect light passing through the sample, and a computer in communication with the excitation light source, the fluorescence detector, and the absorption detector, the computer controlling the excitation light source to sequentially illuminate the sample with each of the plurality of wavelengths while measuring absorption and fluorescence of the sample based on signals received from the fluorescence and absorption detectors.

Abstract: Variables utilized in device firmware that provides various boot and runtime services are repaved in a fault-tolerant manner within a secure store in a durable, non-volatile device memory during an FOTA update process. A spare region in the secure store is utilized to temporarily hold a back-up of a primary region in which the firmware variables are written. Using a transaction-based fault-tolerant write (FTW) process, the variables in the primary region can be repaved with variables contained in a firmware update payload that is delivered from a remote service. In the event of a fault in the variable region repaving process, either the primary or spare region will remain valid so that firmware in a known good state can be utilized to enable the device to boot successfully and the variable region repaving in the FOTA update process may be restarted.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.